NRG-HN002 & NRG-HN005 (HPV+ de-escalation)
Attempts to give HPV-positive throat cancer patients less radiation fell short: the standard dose remained better, so de-escalation is not yet routine.
HN002 (phase 2, 2021) found 60 Gy with weekly cisplatin met its acceptability threshold, but 60 Gy alone did not. HN005 (phase 2/3, presented 2025) was stopped after the de-intensified arms showed diminished progression-free survival while the 70 Gy control reached 2-year PFS of 98%. HPV status alone is an insufficient selector; ctHPV-DNA and imaging-response-adapted designs are the next approach.
Pages like this
not linked directly; found by shared links- TechnologyCirculating tumour HPV DNA (ctHPV-DNA)
Shares Caution: de-escalating radiation on HPV status alone, ctHPV-DNA-adapted de-escalation of chemoradiation, HPV-positive (p16) head and neck cancer, Head and neck squamous cell carcinoma.
- TrialRTOG 0129 (HPV analysis)
Shares HPV-positive (p16) head and neck cancer, IMRT / IGRT (modern external beam), Head and neck squamous cell carcinoma.
- PersonDeborah Watkins Bruner
- IdeaPhotobiomodulation and a taste and swallowing programme for mouth and throat toxicity
Shares IMRT / IGRT (modern external beam), Head and neck squamous cell carcinoma.
- IdeaA standing platform for testing new drugs with radiotherapy
- TrialTrilynX
Shares IMRT / IGRT (modern external beam), Head and neck squamous cell carcinoma.
- PersonLori J. Pierce
- TrialOUTBACK / ANZGOG 0902 / GOG-0274